Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?

Simple item page
AuthorEwa Otto-Buczkowskaen
AuthorNatalia Jaintaen
Issued Date2018-01-31en
AbstractThe basis of treatment in autoimmune diabetes is insulin therapy; however, many clinical cases have proven that this method does not solve all problems. Trials of causal treatment including blocking the autoimmune processes and insulin-producing cells transplants were carried out. Those methods require more research to be concerned as efficient and safe ways of treatment in type 1 diabetes. The use of non-insulin adjunct treatment is a new trend. It has been successfully used in laboratories as well as clinical trials. Metformin is the most widely used drug, together with sodium-glucose co-transporters 2 (SGLT2) inhibitors, amylin analogues, glucagon-like peptide 1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors. The results of administration of these medicaments give good outcomes in patients with diabetes mellitus type 1. Most likely, in the near future, they will progressively be used in both adult and adolescent patients with type 1 diabetes. Further multicenter, randomized studies are required to evaluate the efficacy of treatment and long term safety of these drugs.en
DOIhttps://doi.org/10.5812/ijem.13008en
KeywordType 1 Diabetesen
KeywordInsulin Therapyen
KeywordNon-Insulin Adjunct Therapyen
KeywordMetforminen
KeywordSGLT2: Sodium-Glucose Co-Transportersen
KeywordAmylin Analogueen
KeywordGlucagon-Like Peptide 1 (GLP-1) Receptor Agonistsen
KeywordDipeptidyl Peptidase-4 (DPP-4) Inhibitorsen
PublisherBrieflandsen
TitlePharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?en
TypeReview Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijem-16-01-13008.pdf
Size:
124.41 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

International Journal of Endocrinology and Metabolism